Rare adverse drug reaction associated with COVID-19 vaccine – case report
Case Report
DOI:
https://doi.org/10.53411/jpadr.2021.2.4.7Keywords:
COVID – 19 vaccine, adverse drug reaction, urticarial vasculitis, erythematous macules, bullous lesionsAbstract
Introduction: India began to administer COVID-19 vaccines on 16 January 2021. As of 31 July 2021, the number of Covid-19 vaccine doses administered in the country has crossed 46 crores. Many adverse drug reactions were reported ranging from mild to severe and common to uncommon.
Case Presentation: Here we report a case of a 50-year-old woman with erythematous macules, plaques, and multiple bullous lesions after vaccination for COVID-19. Blood investigations, histopathological examination, direct immunofluorescence tests were done and diagnosed as Urticarial Vasculitis. She was treated with steroids, antihistamines, antibiotics, and vitamin supplements. She was discharged after one week with oral drugs. As the patient was treated early with prompt medical management she was recovered without any morbidity.
References
Chang, S., & Carr, W. (2007). Urticarial vasculitis. Allergy and asthma proceedings, 28(1), 97–100.
Kulthanan, K., Cheepsomsong, M., & Jiamton, S. (2009). Urticarial vasculitis: etiologies and clinical course. Asian Pacific journal of allergy and immunology, 27(2-3), 95–102.
Mallapaty S. (2021). India's massive COVID surge puzzles scientists. Nature, 592(7856), 667–668.
Manjaly Thomas, Z. R., Leuppi-Taegtmeyer, A., Jamiolkowski, D., Steveling-Klein, E., Bellutti-Enders, F., Scherer Hofmeier, K., & Hartmann, K. (2020). Emerging treatments in COVID-19: Adverse drug reactions including drug hypersensitivities. The Journal of allergy and clinical immunology, 146(4), 786–789.
Padma T. V. (2021). India's COVID-vaccine woes - by the numbers. Nature, 592(7855), 500–501.
Sun, J., Deng, X., Chen, X., Huang, J., Huang, S., Li, Y., Feng, J., Liu, J., & He, G. (2020). Incidence of Adverse Drug Reactions in COVID-19 Patients in China: An Active Monitoring Study by Hospital Pharmacovigilance System. Clinical pharmacology and therapeutics, 108(4), 791–797.
Published
Issue
Section
License
Copyright (c) 2021 Sailaja Priyadarsini Parlapalli, Sekhar Bandar, Upendra Kumar Mudaragadda
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
